LXRX:NGS-Lexicon Pharmaceuticals Inc. (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 1.65

Change

+0.11 (+7.14)%

Market Cap

USD 1.71B

Volume

7.09M

Analyst Target

USD 4.70
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Lexicon Pharmaceuticals Inc operates as a biopharmaceutical company engaged in discovery and development of breakthrough treatments for human disease.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-01 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+8.90 (+2.08%)

USD 109.10B
REGN Regeneron Pharmaceuticals Inc

-6.43 (-0.65%)

USD 107.30B
MRNA Moderna Inc

+0.74 (+0.58%)

USD 44.96B
ARGX argenx NV ADR

+20.95 (+5.88%)

USD 23.18B
BNTX BioNTech SE

-0.08 (-0.09%)

USD 22.34B
ALNY Alnylam Pharmaceuticals Inc

-0.49 (-0.33%)

USD 18.96B
BGNE BeiGene Ltd

+4.11 (+2.56%)

USD 18.28B
GMAB Genmab AS

+0.69 (+2.34%)

USD 18.26B
RPRX Royalty Pharma Plc

+0.14 (+0.50%)

USD 16.78B
BMRN Biomarin Pharmaceutical Inc

+0.75 (+0.94%)

USD 15.29B

ETFs Containing LXRX

BBP Virtus LifeSci Biotech Pr.. 2.71 % 0.79 %

+0.87 (+1.55%)

USD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.84% 64% D 76% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.84% 64% D 75% C
Trailing 12 Months  
Capital Gain -39.78% 41% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -39.78% 41% F 23% F
Trailing 5 Years  
Capital Gain -74.85% 44% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -74.85% 44% F 17% F
Average Annual (5 Year Horizon)  
Capital Gain 17.79% 71% C- 78% C+
Dividend Return 17.79% 71% C- 77% C+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 99.92% 26% F 16% F
Risk Adjusted Return 17.80% 74% C 55% F
Market Capitalization 1.71B 67% D+ 60% D-

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 16.96 32% 51%
Price/Book Ratio 5.21 28% 22%
Price / Cash Flow Ratio -2.40 50% 68%
Price/Free Cash Flow Ratio -2.58 62% 70%
Management Effectiveness  
Return on Equity -168.50% 27% 13%
Return on Invested Capital 25.47% 91% 91%
Return on Assets -50.67% 25% 9%
Debt to Equity Ratio 106.87% 17% 22%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector